AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Teva Pharmaceutical on 7/10 was $138.60 Million, Ranking 701
ByAinvest
Thursday, Jul 10, 2025 6:00 pm ET1min read
The turnover of Teva Pharmaceutical on 7/10/2025 was $138.60 million, ranking 701 in today's market, the Volume is 8.36 million.
Teva Pharmaceutical(TEVA) shares closed at $16.53, down 1.08% on 7/10/2025, down 2.82% in the last 5 trading days, down 1.37% this month, down 25.00% year-to-date and down 3.33% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 7/10/2025 | $138.60 million | 8.36 million | $16.53 | -1.08% |
| 7/9/2025 | $184.53 million | 10.99 million | $16.71 | 0.48% |
| 7/8/2025 | $180.18 million | 10.80 million | $16.63 | -1.31% |
| 7/7/2025 | $164.00 million | 9.69 million | $16.85 | -0.94% |
| 7/3/2025 | $94.54 million | 5.55 million | $17.01 | -0.23% |
【Company Profile】
Teva Pharmaceutical Industries Limited was incorporated in Israel on February 13, 1944. The company is a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. The company mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients. The company operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet